Nicholas Mignemi, Ph.D

Official Affiliation: Molecular Physiology and Biophysics

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Plasmin Prevents Dystrophic Calcification After Muscle Injury. Mignemi NA, Yuasa M, Baker CE, Moore SN, Ihejirika RC, Oelsner WK, Wallace CS, Yoshii T, Okawa A, Revenko AS, MacLeod AR, Bhattacharjee G, Barnett JV, Schwartz HS, Degen JL, Flick MJ, Cates JM, Schoenecker JG (2017) J Bone Miner Res 32(2): 294-308
    › Primary publication · 27530373 (PubMed)
  2. Validation of a Radiography-Based Quantification Designed to Longitudinally Monitor Soft Tissue Calcification in Skeletal Muscle. Moore SN, Hawley GD, Smith EN, Mignemi NA, Ihejirika RC, Yuasa M, Cates JM, Liu X, Schoenecker JG (2016) PLoS One 11(7): e0159624
    › Primary publication · 27438007 (PubMed) · PMC4954695 (PubMed Central)
  3. The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent adduction of antithrombin III. Jacobson R, Mignemi N, Rose K, O'Rear L, Sarilla S, Hamm HE, Barnett JV, Verhamme IM, Schoenecker J (2014) Thromb Res 134(6): 1350-7
    › Primary publication · 25307422 (PubMed) · PMC4337957 (PubMed Central)
  4. The temporal and spatial development of vascularity in a healing displaced fracture. Yuasa M, Mignemi NA, Barnett JV, Cates JM, Nyman JS, Okawa A, Yoshii T, Schwartz HS, Stutz CM, Schoenecker JG (2014) Bone : 208-21
    › Primary publication · 25016962 (PubMed)
  5. Micro-computed tomography assessment of the progression of fracture healing in mice. O'Neill KR, Stutz CM, Mignemi NA, Burns MC, Murry MR, Nyman JS, Schoenecker JG (2012) Bone 50(6): 1357-67
    › Primary publication · 22453081 (PubMed)
  6. Fracture healing in protease-activated receptor-2 deficient mice. O'Neill KR, Stutz CM, Mignemi NA, Cole H, Murry MR, Nyman JS, Hamm H, Schoenecker JG (2012) J Orthop Res 30(8): 1271-6
    › Primary publication · 22247070 (PubMed)
  7. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma. Ichikawa J, Cole HA, Magnussen RA, Mignemi NA, Butler M, Holt GE, O'Rear L, Yuasa M, Pabla B, Haro H, Cates JM, Hamm HE, Schwartz HS, Schoenecker JG (2012) Cancer 118(9): 2494-506
    › Primary publication · 21953059 (PubMed)
  8. 2010 Young Investigator Award winner: Therapeutic aprotinin stimulates osteoblast proliferation but inhibits differentiation and bone matrix mineralization. Schoenecker J, Mignemi N, Stutz C, Liu Q, Edwards J, Lynch C, Holt G, Schwartz H, Mencio G, Hamm H (2010) Spine (Phila Pa 1976) 35(9): 1008-16
    › Primary publication · 20407341 (PubMed)
View full member profile

Featured Affiliation

No featured affiliations

    View all affiliations

    Contact Information

    2215 Garland Ave
    813 Light Hall
    Nashville, TN 37232
    USA
    +1 (615) 343-7415 (p)
    Email

    Keywords & MeSH Terms

    MeSH terms are retrieved from PubMed records. Learn more.

    Key: MeSH Term Keyword

    Animals Anticoagulants Antifibrinolytic Agents Antithrombin III Bone Density Bone Neoplasms Bony Callus Calcinosis Cell Differentiation Cell Line Cell Line, Tumor Cells, Cultured Cell Survival Diphosphates Fibrinolysin Fracture Healing Genetic Predisposition to Disease Humans Hyperglycemia Mice Mice, Knockout Muscle, Skeletal Myositis Ossificans Osteogenesis Protein Binding Receptors, Vascular Endothelial Growth Factor Regeneration Vascular Endothelial Growth Factor A X-Ray Microtomography Young Adult